<div id="readability-page-1"><div><h2>Stock performance snapshot and recent context</h2> <p>Gilead Sciences (GILD) has seen its stock pull back recently, with the price declining about 7% over the past month and about 16% over the past 3 months, despite a 1 year total return near 30%.</p> <p>See our latest analysis for Gilead Sciences.</p> <p>The recent pullback, with the share price down about 7% over the past month and about 16% over the past 3 months, contrasts with a much stronger 1 year and multi year total shareholder return. This suggests momentum has cooled after a strong run.</p> <p>If Gilead’s moves have you thinking about where else growth or re rating potential could emerge in healthcare, now is a useful moment to scan 32 healthcare AI stocks</p> <p>So, with Gilead’s share price pulling back even as 1 year and multi year total returns, revenue and net income growth, and value metrics look supportive, is this a fresh entry point, or are markets already pricing in the next leg of growth?</p> <h2>Most Popular Narrative: 18% Undervalued</h2> <p>Gilead Sciences’ most followed narrative pegs fair value at about $157 per share, versus a last close of $129.58, which frames the recent pullback in a very different light.</p> <blockquote> <p><em>The launch and scaling of innovative products (Yeztugo, Trodelvy first-line, Livdelzi) position Gilead to deliver a more favorable product mix and premium pricing, driving higher gross margins and improving long-term earnings trajectory as portfolio diversification reduces overexposure to legacy products.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Want to see what sits behind that confidence in margins and earnings power? The narrative leans on steady top line growth, expanding profitability and a richer product mix to reach its fair value number.</p> <p><strong>Result: Fair Value of $157.43 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this upbeat story still depends on Gilead managing policy and pricing pressure, and successfully turning its oncology and HIV pipeline into durable, widely adopted products.</p> <p>Find out about the key risks to this Gilead Sciences narrative.</p> <h2>Another angle on valuation</h2> <p>On simple P/E math, Gilead trades at 17.5x earnings, which is almost identical to the US Biotechs average at 17.4x, yet sits well below its own fair ratio of 31.4x and the peer average of 41.9x. That mix of tight industry pricing and a wide fair ratio gap raises a practical question for you: is the market being cautious or leaving something on the table?</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb86f0e2-1916-439d-a4b8-74ce7ea1e1c9/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb86f0e2-1916-439d-a4b8-74ce7ea1e1c9/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE2"/><figcaption>NasdaqGS:GILD P/E Ratio as at May 2026</figcaption></figure><h2>Next Steps</h2> <p>With sentiment looking mixed, now is a good time to move quickly and check the balance of concerns and upside for yourself using 5 key rewards and 1 important warning sign</p> <h2>Looking for more investment ideas?</h2> <p>If you stop with just one stock, you might miss opportunities that better fit your goals, income needs, or comfort with risk.</p> <ul> <li>Target resilient income by scanning for 12 dividend fortresses that could complement or balance more growth focused holdings.</li> <li>Hunt for potential mispriced opportunities by reviewing 50 high quality undervalued stocks that align with your return and risk preferences.</li> <li>Prioritize capital preservation by checking 66 resilient stocks with low risk scores that may offer steadier profiles when markets turn choppy.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

GILD

LABU

IBBQ

<p>Gilead Sciences (GILD) has experienced a stock pullback of 7% in the past month and 16% over three months, despite a 30% total return over the past year. Analysts suggest the stock is undervalued at $157 per share compared to its recent close of $129.58. The company’s innovative product launches may enhance margins and earnings, but success depends on managing pricing pressures and developing its oncology and HIV pipeline. Gilead's P/E ratio is 17.5, below its fair ratio of 31.4, raising questions about market caution.</p>

Simplywall

Gilead Sciences

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

A Look At Gilead Sciences (GILD) Valuation After The Recent Share Price Pullback